CX-5461

Research use only, not for human use.

CX-5461 is the first potent, selective, orally bioavailable inhibitor of RNA polymerase I.

CX-5461 is the first potent, selective, orally bioavailable inhibitor of RNA polymerase I, selectively inhibits rRNA synthesis in HCT-116 cells with IC50 of 142 nM, 200-fold selectivity over Pol II; inhibits the initiation stage of rRNA synthesis and induces both senescence and autophagy, but not apoptosis, through a p53-independent process in solid tumor cell lines; demonstrates in vivo antitumor activity against human solid tumors in murine xenograft models.Solid Tumors Phase 2 Clinical

CX 5461;CX5461

Cell Cycle/DNA Damage

DNA/RNA Synthesis

PolI-driventranscriptionofrRNA

Cancer

Solid Tumors

1138549-36-6

513.61

C27H27N7O2S

>98% (HPLC)

DMSO: < 5.3 mg/mL

O=C(C1=C(SC2=CC=CC=C23)N3C4=C(C=CC(N5CCN(C)CCC5)=N4)C1=O)NCC6=NC=C(C)N=C6

5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-

(-20℃)

With Ice Pack

≥ 2 years